Dengue Vaccine Market Size to Grow by $ 132.90 Million through 2021-2025
Technavio research projects the dengue vaccine market to grow by $ 132.90 million, accelerating at a CAGR of over 18% till 2025. The growth trajectory of the market is traced through a detailed analysis of the prevalent market forces, trends, and drivers along with competitive benchmarking
Dengue Vaccine Market: Receive FREE Sample Report
Dengue Vaccine Market: Key Market Driver
One of the primary factors that will trigger the growth of the dengue vaccine market size is Rapid growth in disease prevalence. This research report provides a comprehensive analysis of all the factors that are likely to propel market growth, taking into account the market trends as well as challenges that are likely to impede growth. The objective of this research report is to equip clients with actionable insights that will help them leverage opportunities and formulate growth strategies for their business.
Dengue Vaccine Market: Vendor Analysis
The market is fragmented due to the presence of several players. The growth of the players depends on several factors such as market conditions, government support, and industry development. To survive and succeed in such an intensely competitive market, players must distinguish their product and service offerings through clear and unique value propositions. BioNet-Asia Co. Ltd., Chula VRC, Codagenix Inc., Emergex Vaccines Holding Ltd., GeneOne Life Science Inc., Imutex Ltd., KM Biologics Co. Ltd., Medigen Biotechnology Corp., Najít Technologies Inc., and Sanofi SA are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their position in the slow-growing segments.
Explore Technavio’s Research on other Related Markets for more insights:
Technavio also offers custom research reports with detailed insights assessing the market from a global as well as regional perspective. This customized report will help clients keep up with new product launches in direct & indirect or related markets. It will also provide insights on upcoming developments along with a pipeline analysis of vendor operations and the impact of government regulations.For more insights on this market: Download a Free Sample Report
Technavio has been monitoring the Global Dengue Vaccine Market and it is expected to grow by USD 630.65 million progressing at a CAGR of over 26% during the forecast period. The growth trajectory of the market is traced through a detailed analysis of the prevalent market forces, trends, and drivers along with competitive benchmarking. Download latest version with COVID-19 analysis Free Sample Report
North America to account for 57% growth
Dengue fever, also known as breakbone fever, is a mosquito-borne infection that can lead to a severe flu-like illness. It is caused by four different viruses and spread by the Aedes mosquitoes. Factors such as rapid growth in disease prevalence, ineffective dengue control measures, and initiatives for dengue vaccine research and dengue immunization programs will offer immense growth opportunities. 57% of the market’s growth will originate from North America during the forecast period, with the US being the key market for dengue vaccine in North America. This report provides an accurate prediction of the contribution of all the geographic segments to the growth of the dengue vaccine market market size.
The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment.
Dengue Vaccine Market: Vendor Analysis
The market is fragmented. The growth of the players depends on several factors such as market conditions, government support, and industry development. To survive and succeed in such an intensely competitive market, players must distinguish their product and service offerings through clear and unique value propositions. Avida-Biotech, Emergex Vaccines Holding Ltd., GeneOne Life Science Inc., Imutex Ltd., KM Biologics Co. Ltd., Medigen Biotechnology Corp., Panacea Biotec Ltd, Sanofi, Takeda Pharmaceutical Co. Ltd., and VLP Therapeutics LLCare some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their position in the slow-growing segments. However, regulatory hurdles in vaccine penetration, issues in pre-clinical development of dengue vaccine, and complexities in clinical development of dengue vaccine may impede market growth.
Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19 Download a Free Sample Report
Dengue Vaccine Market: Key Highlights of the Report for 2020-2024
